Ulcerative colitis (UC) and Crohn’s disease (CD) are the two more frequent and common forms of inflammatory bowel disease. These two deseases present with distinct pathogenesis, symptomatology, inflammatory profiles and gut microbiota composition. In UC inflammation affects only the superficial layers of the intestinal mucosa and is localized from the distal colon to the rectum. Whereas in CD inflammation occurs anywhere along the digestive tract and may extend deeply into the submucosal regions.
For both disease causes are unknown, however they are thought to be due to a multifactorial process.
Important factors are genetic predisposition, various environmental factors, altered immune reactions and food choices, which result in destruction of the mucosal barrier. Gut microbiota is no doubt implicates in IBD pathogenesis. In fact, faeces or intestinal epithelial tissue samples of patients with IBD are altered compositions and concentrations of bacterial strains than healthy individuals.
Let us mention here some therapeutic treatments for colitis, which is considerably more frequent than Crohn’s disease. UC manifests itself with various symptoms like diarrhea with blood and mucus mixed with pus in the stool, abdominal pain prior to the evacuation, fever, weight loss, anemia, iron deficiency anemia and sometimes extra intestinal tissue disorders. Other long-term side effects may appear. UC May have a chronic course with recurrence alternating with periods of wellness.
During acute phase medical therapy is intravenous cortisone first (stopping oral feeding) and then orally and enemas cortisone. In remission, suspended the cortisone, are generally salazopyrin or mesalazine, tyopurin, anti TNF and probiotics. In particular, the probiotic strain Escherichia Coli Nissle 1917 called in Italy EcN ® (Mutaflor in Germany) has demonstrate a hight efficacy in the treatment of UC.
This product offers a large safe use and performs various actions that combat the symptoms of UC increasing the period of remission with a good quality of life. EcN modulates the bacterial flora by eliminating pathogens and decreasing inflammatory State. It also acts on the intestinal epithelium, reinforcing the action of intestinal barrier and strengthening immune reaction.
The EcN probiotic cells, secured in gastro-resistant hard coating, have released only when they reach the terminal ileum.
As a result of several clinical work, European Crohn’s and Colitis Organization (ECCO) guidelines indicate Escherichia Coli Nissle 1917 as the most effective and documented strain of probiotics to use for maintenance of remission of Ulcerative Colitis, alternatively or associated to mesalazine.
Adults and teenagers should take 1 capsule EcN daily from day 1 to day 4, than the standard dose is 2 capsules EcN daily for the whole remission period.
The product is now available in Italy under the name EcN in all pharmacies and ecommerce website www.cadigroup-shop.eu